Multiple Myeloma Clinical Trial
Official title:
Phase 1 Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma
This study has 2 parts: a Dose Escalation Part and a Dose Expansion Part.
The goal of the Dose Escalation Part of this clinical research study is to find the highest
tolerable dose of nivolumab in combination with ipilimumab and the standard of care
(lenalidomide and dexamethasone) that can be given to patients with multiple myeloma (MM).
The goal of the Dose Expansion Part of this clinical research study is to continue to study
the safety of the highest tolerable dose found in Phase 1 of the study.
Study Groups:
If participant is found to be eligible to take part in this study, participant will be
assigned to a study group based on when participant joins this study. Up to 2 groups of up to
6 participants each will be enrolled in the Dose Escalation Part of the study, and up to 24
participants will be enrolled in the Dose Expansion Part.
If participant is enrolled in the Dose Escalation Part, the dose of nivolumab participant
receives will depend on when participant joins this study. The first group of participants
will receive the lowest dose level of nivolumab. A second group will then receive a higher
dose of nivolumab than the group before it, if no intolerable side effects were seen.
If participant is enrolled in the Dose Expansion Part, participant will receive nivolumab at
the highest dose that was tolerated in the Dose Escalation Part.
All participants will receive the same dose levels of ipilimumab, dexamethasone, and
lenalidomide.
Study Drug Administration:
The first 4 study cycles will be 21 days long, and all remaining cycles will be 28 days long.
On Day 1 of Cycles 1-4, participant will receive nivolumab by vein over 60 minutes. Thirty
(30) minutes after participant receives nivolumab, participant will receive ipilimumab by
vein over 90 minutes. On Days 1 and 15 of Cycles 5 and beyond, participant will receive
nivolumab by vein over 60 minutes.
Participant will take tablets of lenalidomide on Days 1-14 of Cycles 1-4 and on Days 1-21 of
Cycles 5 and beyond. Participant will take tablets of dexamethasone on Days 1, 8, and 15 of
Cycles 1-4, and on Days 1, 8, 15, and 22 of Cycles 5 and beyond.
Study Visits:
On Day 1 of Cycles 1- 4 (+/- 7 days):
- Participant will have a physical exam.
- Blood (about 3 tablespoons) will be drawn for routine tests, biomarker testing, and to
check the status of the disease. If participant can become pregnant, this routine
testing will also include a pregnancy test.
- Urine will be collected over 24 hours for routine tests and to check the status of the
disease.
- During Cycle 3 only, participant will have 2 bone marrow biopsies/aspirations to check
the status of the disease and for biomarker testing, including genetic biomarkers.
- During Cycle 3 only, urine will be collected for biomarker testing.
At the end of Cycle 4, participant will have an ECHO and pulmonary function test to check the
status of participant's lungs and heart.
On Day 1 of Cycles 5 and beyond:
- Participant will have a physical exam.
- Blood (about 2 tablespoons) and urine will be collected for routine tests and to check
the status of the disease. If participant can become pregnant, this routine testing will
also include a pregnancy test.
- Urine will be collected over 24 hours for routine tests and to check the status of the
disease.
- Some participants will have a stem cell transplant after Cycle 4. If participant does
not have a stem cell transplant, blood (about 1 tablespoon) will be drawn for tests of
the immune system every cycle. If participant does have a stem cell transplant, this
will only be done every 3 cycles.
- If participant does not have a stem cell transplant, on Day 1 of Cycles 5 and every 3
cycles after that, urine will be collected for biomarker testing.
On Day 15 of Cycles 5 and beyond, blood (about 1 tablespoon) will be drawn for routine tests.
If at any point participant does have a stem cell transplant, participant will have 2 bone
marrow biopsies or aspirations to check the status of the disease and for biomarker testing
after the transplant.
End-of-Treatment Visits:
When participant stops taking the study drug:
- Blood (about 1-2 tablespoons) and urine will be collected for routine tests, to check
the status of the disease, and to learn how the study drugs work in participant's body.
If participant can become pregnant, part of this blood will be used for a pregnancy
test.
- Participant will have 2 bone marrow biopsies/aspirations to check the status of the
disease and for biomarker testing, including genetic biomarkers.
If at any point the disease gets worse:
- Blood (about 2 tablespoons) and urine will be collected for routine tests and to check
the status of the disease.
- Urine will be collected over 24 hours for routine tests and to check the status of the
disease.
- Participant will have a bone survey to check the status of the disease.
- Participant will have a bone marrow biopsy or aspiration to check the status of the
disease and for biomarker testing, including genetic biomarkers.
- Blood (about 3 teaspoons) will be drawn for genetic testing to learn if there is a
relationship between participant's genes and the disease
Follow-Up:
If the doctor thinks it is needed, participant may have the following tests. The schedule for
these tests will depend on what participant's doctor thinks is in participant's best
interest.
- Blood (about 2 tablespoons) and urine will be collected for routine tests and to check
the status of the disease. If participant can become pregnant, this routine testing will
also include a pregnancy test.
- Urine will be collected over 24 hours for routine tests and to check the status of the
disease.
- Participant will have bone marrow biopsies or aspirations to check the status of the
disease and for biomarker testing, including genetic biomarkers.
- Participant will have a bone survey to check the status of the disease.
This is an investigational study. Nivolumab and ipilimumab are FDA approved for the treatment
of certain types of melanoma. Their use in patients with MM is investigational. Lenalidomide
in combination with dexamethasone is FDA approved for the treatment for multiple myeloma. The
study doctor can explain how the study drugs are designed to work.
Up to 36 participants will be enrolled in this study. All will take part at MD Anderson.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
| Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
| Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
| Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
| Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
| Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
| Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
| Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
| Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
| Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |